137P Phase I dose-finding study of a novel anti-CTLA-4 antibody ADG116 as monotherapy in patients with advanced solid tumors

ADG116 is a novel human anti-CTLA-4 IgG1 antibody. It targets a novel epitope and is more potent but safer than ipilimumab in preclinical studies through two distinct mechanisms: 1) effective T cell activation by softer blocking the interaction between CTLA-4 and its ligands, and 2) stronger ADCC-mediated Treg depletion in tumor microenvironment but not in peripheral tissues. Combination of both effects gives rise to a stronger Teff/Treg ratio than ipilimumab in head-to-head preclinical studies.